Bright Minds Biosciences (DRUG) Operating Expenses (2020 - 2026)

Bright Minds Biosciences has reported Operating Expenses for 7 years, with the latest figure at -$9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 508.37% year-over-year to -$9.6 million; the trailing twelve-month figure through Mar 2026 stood at -$3.1 million (down 199.7% YoY), and the FY2025 full-year result was $10.0 million, up 381.22% from the prior year.
• Operating Expenses for Q1 2026 stood at -$9.6 million, down from -$6.0 million in the prior quarter.
• The five-year high for Operating Expenses was $16.8 million in Q3 2025, with the low at -$9.6 million in Q1 2026.
• Historically, Operating Expenses has averaged $706999.0 across 5 years, with a median of $873041.0 in 2023.
• The largest YoY upside for Operating Expenses was 2842.82% in 2025 against a maximum downside of 18642.06% in 2025.
• Bright Minds Biosciences' Operating Expenses stood at $1.1 million in 2022, then retreated by 15.2% to $951047.2 in 2023, then tumbled by 96.59% to $32422.2 in 2024, then tumbled by 18642.06% to -$6.0 million in 2025, then plunged by 59.5% to -$9.6 million in 2026.
• The last three Operating Expenses figures came in at -$9.6 million (Q1 2026), -$6.0 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.